“We don’t yet have the data to know how effectively an intradermal-administered [monkeypox] vaccination will protect immunocompromised persons," referring to the US Food and Drug Administration plan to inject one-fifth of the normal vaccine dose under the top layer of skin rather than into fatty tissue, a strategy to immunize more people against the poxvirus.